Back to top

Evommune initiates Phase 2b trial of EVO756

Evommune (EVMN) announced the first patient was dosed in its Phase 2b clinical trial evaluating EVO756, for the prophylactic treatment of migraine....

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE: